Market Overview

Benzinga's Top Initiations

Share:
Benzinga's Top Initiations
Related SRPT
Benzinga's Top Upgrades, Downgrades For May 11, 2018
Benzinga's Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down
Related FOSL
53 Biggest Movers From Yesterday
Earnings Scheduled For May 8, 2018

 

  • Analysts at Morgan Stanley initiated coverage on Sarepta Therapeutics Inc (NASDAQ: SRPT) with an Equal-Weight rating. The price target for Sarepta Therapeutics is set to $53. Sarepta shares closed at $44.54 on Wednesday.
  • Analysts at Buckingham initiated coverage on Fossil Group Inc (NASDAQ: FOSL) with an Underperform rating. The price target for Fossil is set to $23. Fossil shares closed at $29.11 on Wednesday.
  • Analysts at Aegis Capital initiated coverage of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) with a Buy rating. The price target for Progenics Pharmaceuticals is set to $11. Progenics Pharmaceuticals shares closed at $5.15 on Wednesday.
  • Needham initiated coverage on AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) with a Buy rating. The price target for AMAG Pharmaceuticals is set to $40. AMAG Pharmaceuticals shares closed at $25.70 on Wednesday.
  • Leerink Swann assumed coverage on Nabriva Therapeutics AG - ADR (NASDAQ: NBRV) with an Outperform rating. Nabriva Therapeutics shares closed at $5.91 on Wednesday.
  • Analysts at Wells Fargo initiated coverage of Glaukos Corp (NYSE: GKOS) with an Outperform rating. Glaukos shares closed at $34.52 on Wednesday.
  • Analysts at RBC Capital initiated coverage on Crossamerica Partners LP (NYSE: CAPL) with a Sector Perform rating. The price target for Crossamerica Partners is set to $28. Crossamerica Partners shares closed at $26.67 on Wednesday.
  • Analysts at H.C. Wainwright initiated coverage on OHR Pharmaceutical Inc (NASDAQ: OHRP) with a Buy rating. The price target for OHR Pharmaceutical is set to $10. OHR Pharmaceutical shares closed at $2.95 on Wednesday.
  • Analysts at Leerink Swann assumed coverage on Paratek Pharmaceuticals Inc (NASDAQ: PRTK) with an Outperform rating. Paratek Pharmaceuticals shares closed at $11.55 on Wednesday.

Latest Ratings for SRPT

DateFirmActionFromTo
May 2018BarclaysUpgradesEqual-WeightOverweight
May 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight
May 2018Credit SuisseMaintainsOutperformOutperform

View More Analyst Ratings for SRPT
View the Latest Analyst Ratings

Posted-In: Top InitiationsInitiation Analyst Ratings

 

Related Articles (AMAG + CAPL)

View Comments and Join the Discussion!